Recursion Pharmaceuticals (RXRX)

• Market cap: $2.11B
• 1 day: -0.41%
• 5 days: 3.21%
• 1 month: -10.72%
• 3 months: -6.58%
• 6 months: -21.72%
• Year to date: -33.01%
• 1 year: -25.69%
• 5 years: -84.57%
• 10 years: -84.57%
• Sector: Healthcare
• Industry: Biotechnology

About: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Employees: 800

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

36% more call options, than puts

Call options by funds: $55.7M | Put options by funds: $41M

24% more repeat investments, than reductions

Existing positions increased: 110 | Existing positions reduced: 89

0.6% more ownership

Funds ownership: 77.01% [Q1] → 77.61% (+0.6%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 9 [Q1] → 9 (+0) [Q2]

2% less capital invested

Capital invested by funds: $1.61B [Q1] → $1.57B (-$39.8M) [Q2]

5% less first-time investments, than exits

New positions opened: 57 | Existing positions closed: 60

1% less funds holding

Funds holding: 333 [Q1] → 329 (-4) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5
• Avg. target: $6.5
• High target: $8

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

Needham Gil Blum	$8	Buy Reiterated	11 Sep 2025
Morgan Stanley Vikram Purohit	$5	Equal-Weight Assumed	3 Jul 2025